Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of WD-890 in Healthy Chinese Subjects
NCT06506591Phase 1Completed
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WD-890 in psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD) and 1 more (5 arms), sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd. Primary endpoints: Safety of a single oral dose of WD-890, Tolerability of a single oral dose of WD-890 and 11 more. Started Oct 2023; status: completed.
02
Drugs
WD-890
03
Conditions
psoriasissystemic lupus erythematosus (SLE)inflammatory bowel disease (IBD)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06506591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506591.